Will cell and gene ther­a­py (CGT) man­u­fac­tur­ing inevitably move to small batch and sin­gle dose pro­duc­tion?
How can we ensure sus­tain­able man­u­fac­tur­ing and make these life-sav­ing ther­a­pies avail­able for more patients in need?

Togeth­er with our part­ners from Lim­u­la, Tech­nis­che Uni­ver­sität Wien, Stem­mat­ters, Exothera from the PAT4CGT Project con­sor­tium here is our stance on this top­ic up for dis­cus­sion in the opin­ion paper:
CGT 4.0: a dis­tant dream or inevitable future? Smart process automa­tion is crit­i­cal to make effi­cient scal­a­bil­i­ty of CGT man­u­fac­tur­ing a reality

DOI: 10.3389/fbioe.2025.1563878

Vis­it our Con­tact Page to inquire abou how we can con­tribute to your CGT and Advanced Ther­a­pies pro­duc­tion and ana­lyzis equipment!